The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: Long-term studies using the intratumoral aromatase postmenopausal breast cancer model

Clinical Cancer Research

Volumn 8, Issue 7, 2002, Pages 2378-2388

  Long, Brian J ^a   Jelovac, Danijela ^a   Thiantanawat, Apinya ^a   Brodie, Angela M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; ESTROGEN; ESTROGEN RECEPTOR; FORMESTANE; FULVESTRANT; HORMONE RECEPTOR; LETROZOLE; TAMOXIFEN; AROMATASE; DRUG DERIVATIVE; ENZYME INHIBITOR; ESTRADIOL; NITRILE; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST TUMOR; CANCER CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; DISEASE MODEL; DRUG EFFECT; ENZYMOLOGY; EXPERIMENTAL NEOPLASM; FEMALE; GENETICS; IN VITRO STUDY; METABOLISM; NEOPLASM; NUDE MOUSE; PATHOLOGY;

ANIMAL; AROMATASE; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; HUMAN; IN VITRO; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; RECEPTORS, ESTROGEN; SUPPORT, U.S. GOV'T, P.H.S.; TAMOXIFEN; TRIAZOLES; TUMOR CELLS, CULTURED; ANIMALS; AROMATASE INHIBITORS; HUMANS;

EID: 0035992421     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Antiestrogens in the management of hormone-dependent breast cancer
2. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials among 31,000 recurrences and 24,000 deaths among 75,000 women
3. Antiestrogens: Clinical applications of pharmacology
4. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
5. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update from two mature phase III trials
6. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
7. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial
8. Letrozole, a new oral aromatase inhibitor: Randomized trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer
9. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomised Group Efficacy and Tolerability study
10. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women; results of a North American multi-center randomised trial
11. Anastrozole is superior to tamoxifen as first-line therapy in hormone-receptor positive advanced breast cancer
12. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: A randomized, double-blind, single-center study
13. Promising activity and safety of exemestane (E) as first-line hormonal therapy (HT) in metastatic breast cancer (MBC) patients (pts): Final results of an EORTC randomized phase II trial
14. Exemestane as neoadjuvant treatment for locally advanced breast cancer: Endocrinologic and clinical endpoints
15. Superior efficacy of letrozole (Femara) versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group
16. Letrozole is more effective neoadjuvant therapy than tamoxifen for Erb-1- and/or Erb-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial
17. Letrozole as primary medical therapy for locally advanced and large operable breast cancer
18. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal (PM) women
19. Efficacy of tamoxifen following Arimidex (anastrozole) as first-line treatment for advanced breast cancer (ABC) in postmenopausal (PM) women
20. A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene
21. Effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model
22. Oestradiol synthesis by a human breast carcinoma
23. Expression of aromatase protein and mRNA in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancer
24. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study
25. Stable expression of human aromatase complementary DNA in mammalian cells: A useful system for aromatase inhibitor screening
26. The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3, 17-dione, on estrogen-dependent processes in reproduction and breast cancer
27. The steroidal antiestrogen ICI 182, 780 is an inhibitor of cellular aromatase activity
28. Changes in epidermal growth factor receptor expression and response to ligand associated with acquired tamoxifen resistance or oestrogen independence in the ZR-75-1 human breast cancer cell line
29. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone dependent cancer
30. The effects of aromatase inhibitors and antiestrogens in the nude mouse model
31. The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer
32. Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications
33. Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells
34. Endogenous concentrations and subcellular distribution of estrogens in normal and malignant human breast tissue
35. Aromatase, 17-β-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women
36. In situ oestrone synthesis in normal breast and breast tumour tissues: Effect of treatment with 4-hydroxyandrostenedione
37. Proliferation, hormone responsiveness and estrogen receptor content of MCF-7 breast cancer cells in the short-term and long-term absence of estrogens
38. Adaption of oestrogen-dependent MCF-7 cells to low oestrogen (phenol red-free) culture
39. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells
40. Aromatase inhibitors and their antitumor effects in model systems
41. Pivotal trials of letrozole: A new aromatase inhibitor
42. Aromatase inhibitors: A dose-response effect?
43. Phase III multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate
44. The effect of alternating letrozole and tamoxifen in comparison to sequential treatment with each drug alone or in combination
45. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: A phase II trial
46. Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilized on formestane therapy
47. Pharmacology of inhibitors of estrogen bio synthesis